RT Journal Article
SR Electronic
T1 Legionnaires’ disease on the rise in Switzerland: A denominator-based analysis of national diagnostic data, 2007-2016
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20114355
DO 10.1101/2020.05.27.20114355
A1 Fischer, Fabienne B.
A1 Schmutz, Claudia
A1 Gaia, Valeria
A1 Mäusezahl, Daniel
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.27.20114355.abstract
AB Purpose The risk of Legionnaires’ disease (LD) is suggested to increase, but the global burden of disease is unknown due to lack of appropriate diagnosis and surveillance systems. In Switzerland, the number of LD cases, captured by the National Notification System for Infectious Diseases, has more than doubled since 2008. The aim of this study is to evaluate disease surveillance data using denominator data i.e. the number of tests performed for Legionella. spp.Methods We collected the testing data for Legionella spp. of 14 Swiss diagnostic laboratories and calculated the positivity rate, which is the rate of the number of positive tests to the number of tests performed.Results The number of positive tests increased proportionally to the number of tests performed; hence the positivity remained stable. However, the cause of the increase in test volume is unclear and has a large impact on the interpretation of the positivity curve. Further, the test outcome was found to be dependent on regional determinants and the diagnostic method applied.Conclusion In concert with the lack of understanding if and at which stage LD is considered in current case management of pneumonia patients, it is difficult to interpret heterogeneities in incidence or underestimation in Switzerland.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swiss Federal Office of Public Health (FOPH, grant number 16.015253) and the Swiss Federal Food Safety and Veterinary Office (FSVO, grant number 307.2/2014/00158).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted under the Epidemics Act (SR 818.101).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, DM, with the permission of the FOPH and the FSVO, upon reasonable request.